在诊断和治疗儿科抗脂综合征的更新
Lucia M Campos1, Paula S Marra2, Clara R Doria2
1Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, Instituto da Criança e do Adolescente, Hospital das Clinicas FMUSP, Av. Dr. Enéas Carvalho de Aguiar, 647 - Cerqueira César, São Paulo, SP, 05403-000, Brazil. lucia@arrudacampos.com.
儿科抗脂综合征 (APS) 往往与成人相比呈现出非血栓性问题和独特特征. 新的治疗方法正在出现,但需要进一步的研究来改善APS儿童的治疗结果.
科学领域:
- 儿科风湿病学 儿科风湿病学
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
背景情况:
- 抗脂综合征 (APS) 是一种重要的自身免疫性疾病.
- 儿科APS (pAPS) 与成人APS相比,具有不同的临床特征和挑战.
- 目前APS的诊断标准主要基于成年人群,因此需要针对儿科的指导方针.
研究的目的:
- 为儿童抗脂综合征的近期进展提供全面的审查.
- 突出关于pAPS的表现,诊断和管理的关键发现.
主要方法:
- 对儿科APS的最新文献进行系统审查.
- 分析临床表现,诊断标准和治疗策略.
主要成果:
- 在儿科APS中,非血栓形成的表现和孕期发病率是常见的.
- 灾难性APS是儿童比成年人更频繁的初始表现.
- 直接口服抗凝剂现在已被批准用于儿科静脉血栓塞;像Rituximab这样的新疗法正在探索严重/耐药病例.
结论:
- 儿科APS是一种复杂的疾病,具有独特的特征.
- 早期复发很常见,与诊断时的年龄较大有关.
- 进一步的大规模前性研究对于完善治疗和改善儿科APS患者的预后至关重要.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
iPS Cell Differentiation
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Phosphoinositides and PIPs
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...


